How were (NVET)'s earnings last quarter?

(NVET) (NASDAQ:NVET) announced its earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.02.

What other stocks do shareholders of (NVET) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (NVET) investors own include Frontline (FRO) , Achillion Pharmaceuticals (ACHN) , Anthera Pharmaceuticals (ANTH) , Sphere 3D (ANY) , Arena Pharmaceuticals (ARNA) , Yamana Gold (AUY) , BioLineRx (BLRX) , Caladrius Biosciences (CLBS) , Genetic Technologies (GENE) and Keryx Biopharmaceuticals (KERX) .

(NVET) (NVET) raised $58 million in an initial public offering (IPO) on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

NASDAQ:NVET

(NVET) (NVET) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free NVET Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $6.72
▼
$6.72
50-Day Range: N/A
52-Week Range: $2.75
▼
$6.76

Volume: N/A
Average Volume: 38,104 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get (NVET) alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About (NVET) Stock (NASDAQ:NVET)

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

NVET Stock News Headlines

January 16, 2023 | msn.com

‘A man who understands Hong Kong’: Beijing’s new liaison office head vows to bridge communication between city and central authorities

December 30, 2022 | msn.com

Prescott has 2 TD passes, Cowboys top banged-up Titans 27-13

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

October 10, 2022 | msn.com

Selena Gomez Talks Mental Health in ‘My Mind and Me’ Trailer

September 29, 2022 | msn.com

COVID in California: Boston sees a ‘worrisome’ virus spike in wastewater

August 18, 2022 | msn.com

"There was a lot of screaming, it was terrifying": City centre workers' fears as man stabbed outside Mile Castle pub in Newcastle

July 1, 2022 | thestreet.com

Nymox Pharmaceutical Corporation News

See More Headlines

Receive NVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (NVET) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/11/2017
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:NVET
CUSIP: N/A
CIK: 1618561
Web: www.nexvet.com
Phone: +353-1-2158100
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

NVET Stock Analysis - Frequently Asked Questions

How were (NVET)'s earnings last quarter?: (NVET) (NASDAQ:NVET) announced its earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.02.
What other stocks do shareholders of (NVET) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other (NVET) investors own include Frontline (FRO), Achillion Pharmaceuticals (ACHN), Anthera Pharmaceuticals (ANTH), Sphere 3D (ANY), Arena Pharmaceuticals (ARNA), Yamana Gold (AUY), BioLineRx (BLRX), Caladrius Biosciences (CLBS), Genetic Technologies (GENE) and Keryx Biopharmaceuticals (KERX).
When did (NVET) IPO?: (NVET) (NVET) raised $58 million in an initial public offering (IPO) on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

This page (NASDAQ:NVET) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

(NVET) (NVET) Stock Price, News & Analysis

About (NVET) Stock (NASDAQ:NVET)

NVET Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

NVET Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info